about
A blueprint for transitioning pharmacy residents into successful clinical faculty members in colleges and schools of pharmacyPF4/heparin antibody testing and treatment of heparin-induced thrombocytopenia in the intensive care unit.Alternative monitoring of argatroban using plasma-diluted thrombin time.Education, training, and academic experience of newly hired, first-time pharmacy faculty members.Novel oral anticoagulants: a review of new agents.To prescribe codeine or not to prescribe codeine?Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.Physicians' intention to prescribe hydrocodone combination products after rescheduling: A theory of reasoned action approach.Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective studyComment: Critical Care Pharmacists and Medication Management in an ICU Recovery CenterClinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic TherapyMedication taking behaviors in patients taking warfarin versus direct oral anticoagulants: A systematic reviewManagement of Anticoagulation with Impella® Percutaneous Ventricular Assist Devices and Review of New LiteratureDrug Enforcement Administration Rescheduling of Hydrocodone Combination Products Is Associated With Changes in Physician Pain Management Prescribing PreferencesHealth care practitioner counseling encourages disposal of unused opioid medicationsA comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysisPredictors of on-site interview selection and admission for a doctor of pharmacy program using the pharmacy college application service (PharmCAS) variables
P50
Q26823657-8BDDAE25-D2EB-4A4D-A5DD-D0A18DE2B84DQ33400056-849E1B6D-ED8C-486D-AA97-42BA653A3116Q33406400-BD0E394A-37DC-4F71-AD53-9FB408401AB1Q33781828-91BAD5C6-EBF6-4028-A6CE-D058C322B6AEQ38128173-CC875B18-585D-412E-8510-BB4ACCE50B76Q38237742-1C94880E-3CA2-404F-A5D6-59A2AA466DB7Q41559648-85929F0C-FEA5-48F6-8BC6-9FEDB90101A2Q42089606-A079FED1-10DF-44EB-9BAD-85CDAB05B5EBQ90784756-852B1EA7-EF88-4137-A270-48D5C588D720Q91312216-9FDE9789-E514-4276-979F-935782AE232DQ91681632-7CCE4B23-D56D-4327-A079-11EACC6CFA7AQ92114103-393342DD-07D0-487C-B679-1B628CADEEFBQ92405906-5F99B363-4EF3-4921-AC9C-CE90922999E2Q92900054-66E1FA85-ADA3-467D-92BD-9E5E3ED9F430Q93044726-89DF2461-6150-4242-8490-38C911186965Q93133193-7AA2CFE1-9B68-47BD-B540-2505A3EFC072Q93374195-100CA425-8FA1-427D-B28C-EDEA3AB9C7CE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Matthew A. Wanat
@ast
Matthew A. Wanat
@en
Matthew A. Wanat
@es
Matthew A. Wanat
@sl
type
label
Matthew A. Wanat
@ast
Matthew A. Wanat
@en
Matthew A. Wanat
@es
Matthew A. Wanat
@sl
prefLabel
Matthew A. Wanat
@ast
Matthew A. Wanat
@en
Matthew A. Wanat
@es
Matthew A. Wanat
@sl
P106
P1153
55652202100
P21
P31
P496
0000-0003-4832-8200